1 unknown. 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Unknown 1 |
Follow Cosmo Technologies Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors CB-03-10 - Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10 | Early Phase 1 | Unknown | Cosmo Technologies Ltd | 90 | 2022-06-14 | 2024-02-07 |
United States (1)
PMID 12538758, PMID 14996737, PMID 21563193, PMID 21868756, PMID 21969517, PMID 22223138, PMID 23341367, PMID 24131140, PMID 24315100, PMID 24615402, PMID 25535299, PMID 25595907, PMID 26115975, PMID 26483423, PMID 26566796, PMID 27300548, PMID 28293120, PMID 28428441, PMID 29158269, PMID 29373071, PMID 7082756